Insider Transactions in Q1 2024 at Dyne Therapeutics, Inc. (DYN)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 12
2024
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,030
-0.68%
|
$25,750
$25.58 P/Share
|
|
Mar 11
2024
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,292
-1.44%
|
$57,300
$25.7 P/Share
|
|
Mar 11
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
19,601
-6.23%
|
$490,025
$25.59 P/Share
|
|
Mar 11
2024
|
Jonathan Mc Neill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,825
+10.08%
|
$89,125
$5.54 P/Share
|
|
Mar 11
2024
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
66,387
-2.84%
|
$1,659,675
$25.89 P/Share
|
|
Mar 11
2024
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.64%
|
$250,000
$5.54 P/Share
|
|
Mar 11
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
2,672
-1.1%
|
$66,800
$25.35 P/Share
|
|
Mar 11
2024
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,585
-1.03%
|
$39,625
$25.7 P/Share
|
|
Mar 11
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,081
-1.35%
|
$52,025
$25.7 P/Share
|
|
Mar 08
2024
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
27,199
-7.31%
|
$734,373
$27.04 P/Share
|
|
Mar 08
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
90,000
-14.43%
|
$2,340,000
$26.5 P/Share
|
|
Mar 08
2024
|
Jonathan Mc Neill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
90,000
+14.56%
|
$450,000
$5.54 P/Share
|
|
Mar 08
2024
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
363,343
-14.86%
|
$9,446,918
$26.47 P/Share
|
|
Mar 08
2024
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
363,343
+18.22%
|
$1,816,715
$5.54 P/Share
|
|
Mar 08
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
86,252
-15.37%
|
$2,242,552
$26.45 P/Share
|
|
Mar 08
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Exercise of conversion of derivative security
|
Direct |
86,252
+17.11%
|
$431,260
$5.54 P/Share
|
|
Mar 07
2024
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,591
-0.85%
|
$39,775
$25.85 P/Share
|
|
Mar 07
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,373
-1.51%
|
$59,325
$25.85 P/Share
|
|
Mar 07
2024
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
9,086
-1.61%
|
$227,150
$25.85 P/Share
|
|
Mar 07
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,434
-1.69%
|
$60,850
$25.85 P/Share
|
|
Mar 07
2024
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,921
-3.07%
|
$257,946
$26.0 P/Share
|
|
Mar 07
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
2,273
-1.83%
|
$56,825
$25.85 P/Share
|
|
Mar 01
2024
|
Atlas Venture Opportunity Fund I, L.P. |
SELL
Open market or private sale
|
Indirect |
17,099
-1.98%
|
$512,970
$30.05 P/Share
|
|
Mar 01
2024
|
Atlas Venture Opportunity Fund I, L.P. |
SELL
Open market or private sale
|
Direct |
29,435
-1.98%
|
$883,050
$30.05 P/Share
|
|
Mar 01
2024
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
46,534
-1.98%
|
$1,396,020
$30.05 P/Share
|
|
Mar 01
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
9,311
-3.5%
|
$260,708
$28.43 P/Share
|
|
Mar 01
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Exercise of conversion of derivative security
|
Direct |
9,311
+6.52%
|
$9,311
$1.03 P/Share
|
|
Mar 01
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
24,260
-5.02%
|
$703,540
$29.0 P/Share
|
|
Mar 01
2024
|
Jonathan Mc Neill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,260
+12.63%
|
$0
$0.73 P/Share
|
|
Mar 01
2024
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
94,480
-4.91%
|
$2,739,920
$29.06 P/Share
|
|
Mar 01
2024
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
94,480
+12.56%
|
$472,400
$5.54 P/Share
|
|
Feb 29
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
3,429
-2.69%
|
$92,583
$27.5 P/Share
|
|
Feb 29
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Exercise of conversion of derivative security
|
Direct |
3,429
+2.62%
|
$3,429
$1.03 P/Share
|
|
Feb 29
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,268
-2.89%
|
$115,236
$27.5 P/Share
|
|
Feb 29
2024
|
Jonathan Mc Neill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,268
+2.81%
|
$0
$0.73 P/Share
|
|
Feb 29
2024
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
5,520
-0.97%
|
$149,040
$27.5 P/Share
|
|
Feb 29
2024
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
5,520
+0.96%
|
$27,600
$5.54 P/Share
|
|
Feb 28
2024
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
190,920
-0.95%
|
$4,773,000
$25.04 P/Share
|
|
Feb 28
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Open market or private sale
|
Indirect |
36,246
-0.76%
|
$906,150
$25.04 P/Share
|
|
Feb 28
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Open market or private sale
|
Direct |
154,674
-1.32%
|
$3,866,850
$25.04 P/Share
|
|
Feb 28
2024
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
407
-0.25%
|
$10,175
$25.0 P/Share
|
|
Feb 27
2024
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
368,699
-1.76%
|
$8,848,776
$24.53 P/Share
|
|
Feb 27
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Open market or private sale
|
Indirect |
69,997
-1.43%
|
$1,679,928
$24.53 P/Share
|
|
Feb 27
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Open market or private sale
|
Direct |
298,702
-2.44%
|
$7,168,848
$24.53 P/Share
|
|
Feb 26
2024
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
248,219
-1.16%
|
$5,709,037
$23.79 P/Share
|
|
Feb 26
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Open market or private sale
|
Indirect |
47,124
-0.94%
|
$1,083,852
$23.79 P/Share
|
|
Feb 26
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Open market or private sale
|
Direct |
201,095
-1.59%
|
$4,625,185
$23.79 P/Share
|
|
Feb 23
2024
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
196,928
-1.8%
|
$4,332,416
$22.7 P/Share
|
|
Feb 23
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Open market or private sale
|
Indirect |
37,386
-1.47%
|
$822,492
$22.7 P/Share
|
|
Feb 23
2024
|
Atlas Venture Fund Xi, L.P. |
SELL
Open market or private sale
|
Direct |
159,542
-2.45%
|
$3,509,924
$22.7 P/Share
|